$ASMB
Assembly Biosciences Inc

2018 Q3 Form 10-Q Financial Statement

#000114420418042893 Filed on August 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2017 Q2
Revenue $4.286M $3.218M $2.359M
YoY Change 61.15% 36.39%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.750M $12.54M $3.800M
YoY Change 85.41% 230.0% 29.25%
% of Gross Profit
Research & Development $19.11M $17.84M $12.13M
YoY Change 74.84% 47.13% 61.26%
% of Gross Profit
Depreciation & Amortization $200.0K $100.0K $50.91K
YoY Change 377.94% 96.41% 182.86%
% of Gross Profit
Operating Expenses $26.86M $30.38M $12.13M
YoY Change 145.77% 150.59% 61.26%
Operating Profit -$22.58M -$27.17M -$13.57M
YoY Change 81.33% 100.23% 29.78%
Interest Expense $1.030M $330.0K -$100.0K
YoY Change 635.71% -430.0% -133.33%
% of Operating Profit
Other Income/Expense, Net $1.034M $326.0K -$101.1K
YoY Change 626.85% -422.37% -133.49%
Pretax Income -$21.54M -$26.84M -$13.67M
YoY Change 75.02% 96.37% 34.63%
Income Tax -$6.000K -$34.00K -$69.51K
% Of Pretax Income
Net Earnings -$21.54M -$26.81M -$13.60M
YoY Change 75.48% 97.12% 33.95%
Net Earnings / Revenue -502.47% -833.04% -576.4%
Basic Earnings Per Share -$0.87 -$1.30
Diluted Earnings Per Share -$0.87 -$1.30 -$784.3K
COMMON SHARES
Basic Shares Outstanding 25.45M shares 17.35M shares
Diluted Shares Outstanding 24.88M 20.54M

Balance Sheet

Concept 2018 Q3 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $233.9M $92.70M $75.60M
YoY Change 252.79% 22.62% 19.06%
Cash & Equivalents $119.8M $54.19M $39.45M
Short-Term Investments $114.2M $38.50M $36.10M
Other Short-Term Assets $3.300M $2.700M $1.000M
YoY Change 230.0% 170.0% 66.67%
Inventory
Prepaid Expenses
Receivables $2.590M $2.126M $1.114M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $239.9M $97.53M $77.70M
YoY Change 249.16% 25.52% 21.22%
LONG-TERM ASSETS
Property, Plant & Equipment $515.8K $639.9K $100.0K
YoY Change -14.03% 539.9% 0.0%
Goodwill $12.64M $12.64M
YoY Change
Intangibles $29.00M $29.00M
YoY Change
Long-Term Investments $1.000M $2.600M $3.300M
YoY Change -28.57% -21.21% -71.05%
Other Assets
YoY Change
Total Long-Term Assets $43.10M $44.89M $45.10M
YoY Change -1.28% -0.47% -15.07%
TOTAL ASSETS
Total Short-Term Assets $239.9M $97.53M $77.70M
Total Long-Term Assets $43.10M $44.89M $45.10M
Total Assets $283.0M $142.4M $122.8M
YoY Change 151.98% 15.98% 4.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.000M $2.500M $700.0K
YoY Change 233.33% 257.14% -70.83%
Accrued Expenses $6.517M $5.080M $6.300M
YoY Change 1.83% -19.37% 142.31%
Deferred Revenue $43.59M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.61M $13.13M $12.00M
YoY Change 19.75% 9.42% 140.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $36.80M $38.10M $43.10M
YoY Change -11.96% -11.6%
Total Long-Term Liabilities $38.93M $40.19M $43.10M
YoY Change -26.49% -6.76% 271.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.61M $13.13M $12.00M
Total Long-Term Liabilities $38.93M $40.19M $43.10M
Total Liabilities $53.54M $53.32M $66.20M
YoY Change -17.88% -19.46% 298.8%
SHAREHOLDERS EQUITY
Retained Earnings -$315.6M -$294.1M
YoY Change
Common Stock $25.46K $20.61K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $229.4M $89.10M $56.50M
YoY Change
Total Liabilities & Shareholders Equity $283.0M $142.4M $122.8M
YoY Change 151.98% 15.98% 4.78%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$21.54M -$26.81M -$13.60M
YoY Change 75.48% 97.12% 33.95%
Depreciation, Depletion And Amortization $200.0K $100.0K $50.91K
YoY Change 377.94% 96.41% 182.86%
Cash From Operating Activities -$16.68M -$16.05M -$12.35M
YoY Change 52.19% 29.96% 82.42%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K -$50.00K $0.00
YoY Change -92.0%
Acquisitions
YoY Change
Other Investing Activities -$73.56M $1.510M -$19.12M
YoY Change 7183.17% -107.9% -384.95%
Cash From Investing Activities -$73.60M $1.460M -$19.12M
YoY Change 4774.17% -107.64% -384.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 155.9M 1.850M 110.0K
YoY Change 59842.31% 1581.82%
NET CHANGE
Cash From Operating Activities -16.68M -16.05M -12.35M
Cash From Investing Activities -73.60M 1.460M -19.12M
Cash From Financing Activities 155.9M 1.850M 110.0K
Net Change In Cash 65.57M -12.74M -31.36M
YoY Change -637.02% -59.37% 52166.67%
FREE CASH FLOW
Cash From Operating Activities -$16.68M -$16.05M -$12.35M
Capital Expenditures -$40.00K -$50.00K $0.00
Free Cash Flow -$16.64M -$16.00M -$12.35M
YoY Change 59.08% 29.55% 82.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.4in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the condensed consolidated financial statements in conformity with the U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.37in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: &quot;times new roman&quot;, serif; font-size: 10pt;">Significant estimates inherent in the preparation of the accompanying condensed consolidated financial statements include recoverability and useful lives (indefinite or finite) of intangible assets, assessment of impairment of goodwill, provisions for income taxes, amounts receivable under the collaboration agreement, and the fair value of stock options, restricted stock units (RSUs) and warrants granted to employees, consultants, directors, investors, licensors, placement agents and underwriters.</div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.37in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Revenues
Revenues
6782925 USD
us-gaap Revenues
Revenues
3043680 USD
CY2018Q2 us-gaap Revenues
Revenues
3217865 USD
CY2017Q2 us-gaap Revenues
Revenues
2359311 USD
CY2018Q2 us-gaap Depreciation
Depreciation
143860 USD
CY2017Q2 us-gaap Depreciation
Depreciation
50914 USD
us-gaap Depreciation
Depreciation
311946 USD
us-gaap Depreciation
Depreciation
82830 USD
CY2018Q2 asmb Future Stock Based Compensation Expense Current
FutureStockBasedCompensationExpenseCurrent
10112053 USD
CY2018Q2 asmb Future Stock Based Compensation Expense Year Two
FutureStockBasedCompensationExpenseYearTwo
10698701 USD
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2601181 USD
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4518128 USD
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54192131 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82033209 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17840128 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12125021 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32381302 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22698760 USD
CY2018Q2 asmb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1394397 USD
CY2017Q4 asmb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
674686 USD
CY2018Q2 asmb Future Stock Based Compensation Expense Year Three
FutureStockBasedCompensationExpenseYearThree
3823450 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
120000 shares
dei Document Type
DocumentType
10-Q
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15671738 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3235908 USD
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11588971 USD
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2011261 USD
dei Amendment Flag
AmendmentFlag
false
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
231559 shares
CY2018Q2 asmb Future Stock Based Compensation Expense Year Four
FutureStockBasedCompensationExpenseYearFour
904725 USD
CY2018Q2 asmb Accured General And Administrative Expenses Current
AccuredGeneralAndAdministrativeExpensesCurrent
1084202 USD
CY2017Q4 asmb Accured General And Administrative Expenses Current
AccuredGeneralAndAdministrativeExpensesCurrent
946186 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18239693 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7842000 USD
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12543658 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3801541 USD
CY2018Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
38480105 USD
CY2017Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
37914482 USD
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2125597 USD
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2273421 USD
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
30383786 USD
CY2017Q2 us-gaap Costs And Expenses
CostsAndExpenses
15926562 USD
us-gaap Costs And Expenses
CostsAndExpenses
50620995 USD
us-gaap Costs And Expenses
CostsAndExpenses
30540760 USD
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5079780 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6139000 USD
CY2018Q2 asmb Futurestockbasedcompensationexpenseyearfive
Futurestockbasedcompensationexpenseyearfive
38214 USD
CY2018Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
31221671 USD
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
1500 shares
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
113119769 USD
asmb Deferred Revenueamortization Period Over Service Tenure
DeferredRevenueamortizationPeriodOverServiceTenure
P10Y
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
177650 USD
CY2018Q2 asmb Future Stock Based Compensation Expense Total
FutureStockBasedCompensationExpenseTotal
25577143 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4946743 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4854373 shares
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
41261695 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-43838070 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-27497080 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-27165921 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13567251 USD
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2731385 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
897400 USD
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q2 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-340984 USD
CY2017Q1 asmb Development Milestone Payments
DevelopmentMilestonePayments
630000000 USD
CY2018Q2 us-gaap Assets Current
AssetsCurrent
97529218 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
123118512 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
44.28
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2018Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
999150 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3343736 USD
CY2018Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
4860 USD
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
dei Entity Registrant Name
EntityRegistrantName
ASSEMBLY BIOSCIENCES, INC.
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
44.85
CY2017Q1 asmb Commercial Milestone Payments
CommercialMilestonePayments
2150000000 USD
CY2018Q2 us-gaap Interest Income Other
InterestIncomeOther
453016 USD
CY2017Q2 us-gaap Interest Income Other
InterestIncomeOther
239858 USD
us-gaap Interest Income Other
InterestIncomeOther
899422 USD
us-gaap Interest Income Other
InterestIncomeOther
376342 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-150250 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-478232 USD
CY2018Q2 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-127234 USD
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2018Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
2204103 USD
CY2017Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
3347213 USD
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1365666 USD
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-101126 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
749172 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-101890 USD
CY2018Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
38639018 USD
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
41450363 USD
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5635 USD
CY2018Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
20627 USD
CY2018Q2 us-gaap Security Deposit
SecurityDeposit
406735 USD
CY2017Q4 us-gaap Security Deposit
SecurityDeposit
339558 USD
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26840139 USD
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13668377 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1273849 USD
dei Entity Central Index Key
EntityCentralIndexKey
0001426800
us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
20313 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
49.14
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15671738 USD
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
725769 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
413823 USD
us-gaap Net Income Loss
NetIncomeLoss
-43054991 USD
us-gaap Net Income Loss
NetIncomeLoss
-27529457 USD
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
639897 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
860026 USD
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20614498 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20137974 shares
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
325782 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43088898 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27598970 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
89100565 USD
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-33907 USD
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-69513 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-33907 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-69513 USD
dei Trading Symbol
TradingSymbol
ASMB
CY2018Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
29000000 USD
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
29000000 USD
CY2018Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
179540 USD
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
194303 USD
CY2018Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
38480105 USD
CY2018Q2 us-gaap Goodwill
Goodwill
12638136 USD
CY2017Q4 us-gaap Goodwill
Goodwill
12638136 USD
us-gaap Share Based Compensation
ShareBasedCompensation
15671738 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3235908 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-39962 USD
CY2017Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-31203 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-129937 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-92359 USD
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25446479 shares
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
150250 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
294861 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
127234 USD
CY2017Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
157613 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-150250 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-478232 USD
CY2018Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
44888871 USD
CY2017Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
46184933 USD
CY2018Q2 us-gaap Assets
Assets
142418089 USD
CY2017Q4 us-gaap Assets
Assets
169303445 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-26806232 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-13598864 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-33907 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-69513 USD
CY2017Q1 us-gaap Revenue Recognition Milestone Method Description
RevenueRecognitionMilestoneMethodDescription
the Company is eligible to receive variable consideration in the form of cost-sharing reimbursements, up to approximately $630 million in related to seven development milestones and up to approximately $2.15 billion in related to 12 commercial development and sales milestones in connection with the successful development and commercialization of licensed compounds for up to six different indications.
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-147824 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1113759 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1833985 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
367180 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26718960 USD
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13472454 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43034678 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27326955 USD
CY2018Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000 USD
CY2017Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
800000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
600000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
415037 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1680223 USD
CY2018Q2 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
2538976 USD
CY2017Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
2123939 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1059220 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1552724 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2194534 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
48070080 USD
CY2018Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5512109 USD
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5229227 USD
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
13130865 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13492166 USD
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-67177 USD
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-71884 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31547019 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
22587758 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
91817 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2018Q2 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
2108367 USD
CY2017Q4 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
2135802 USD
CY2018Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
38078292 USD
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
40555708 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
32166978 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
32591164 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
32621000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
20133000 USD
CY2018Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
40186659 USD
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
42691510 USD
CY2018Q2 us-gaap Liabilities
Liabilities
53317524 USD
CY2017Q4 us-gaap Liabilities
Liabilities
56183676 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
362205 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12458164 USD
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
asmb Accrued Offering Cost Related To Issuance Of Common Stock
AccruedOfferingCostRelatedToIssuanceOfCommonStock
3343736 USD
asmb Accrued Offering Cost Related To Issuance Of Common Stock
AccruedOfferingCostRelatedToIssuanceOfCommonStock
748058 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3343736 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
748058 USD
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
20614 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
20138 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-27841078 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10877652 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28575085 USD
CY2018Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
383543035 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
364528037 USD
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-372078 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-392391 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39452737 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-294091006 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-251036015 USD
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
142418089 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
169303445 USD
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2018Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1900000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.11
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.59
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.30
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20541549 shares
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17342623 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20387532 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17305657 shares
CY2018Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
29835 USD
CY2017Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
57437 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
29835 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
57437 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
36307 USD
CY2017Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
183371 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
36307 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
183371 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
6472 USD
CY2018Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
32220821 USD
CY2018Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
182510 USD
asmb Cost Of Reimbursable Expenses
CostOfReimbursableExpenses
200000 USD
CY2017 asmb Cost Of Reimbursable Expenses
CostOfReimbursableExpenses
500000 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
44.64
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
350059 shares
CY2018Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
226208.85 USD
CY2018Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
234137.82 USD
CY2018Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
242533.20 USD
CY2018Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
250928.58 USD
CY2018Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
259790.37 USD
CY2018Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
268652.16 USD
asmb Marketable Securities Available For Sale Change In Before Tax
MarketableSecuritiesAvailableForSaleChangeInBeforeTax
26785 USD
asmb Marketable Securities Available For Sale Change In Before Tax
MarketableSecuritiesAvailableForSaleChangeInBeforeTax
328436 USD
CY2018Q2 asmb Monthly Base Rate Due Next Twelve Months
MonthlyBaseRateDueNextTwelveMonths
4.85
CY2018Q2 asmb Monthly Base Rate Due Year Two
MonthlyBaseRateDueYearTwo
5.02
CY2018Q2 asmb Monthly Base Rate Due Year Three
MonthlyBaseRateDueYearThree
5.20
CY2018Q2 asmb Monthly Base Rate Due Year Four
MonthlyBaseRateDueYearFour
5.38
CY2018Q2 asmb Monthly Base Rate Due Year Five
MonthlyBaseRateDueYearFive
5.57
CY2018Q2 asmb Monthly Base Rate Due After Year Five
MonthlyBaseRateDueAfterYearFive
5.76
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20137974 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20614498 shares

Files In Submission

Name View Source Status
0001144204-18-042893-index-headers.html Edgar Link pending
0001144204-18-042893-index.html Edgar Link pending
0001144204-18-042893.txt Edgar Link pending
0001144204-18-042893-xbrl.zip Edgar Link pending
asmb-20180630.xml Edgar Link completed
asmb-20180630.xsd Edgar Link pending
asmb-20180630_cal.xml Edgar Link unprocessable
asmb-20180630_def.xml Edgar Link unprocessable
asmb-20180630_lab.xml Edgar Link unprocessable
asmb-20180630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv499649_10q.htm Edgar Link pending
tv499649_ex10-1.htm Edgar Link pending
tv499649_ex10-2.htm Edgar Link pending
tv499649_ex10-3.htm Edgar Link pending
tv499649_ex31-1.htm Edgar Link pending
tv499649_ex31-2.htm Edgar Link pending
tv499649_ex32-1.htm Edgar Link pending
tv499649_ex32-2.htm Edgar Link pending